The estimated Net Worth of Viren Mehta is at least $251 Mille dollars as of 25 November 2019. Viren Mehta owns over 250,000 units of Onconova Therapeutics Inc stock worth over $250,857 and over the last 11 years he sold ONTX stock worth over $0. In addition, he makes $0 as Director at Onconova Therapeutics Inc.
Viren has made over 2 trades of the Onconova Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 250,000 units of ONTX stock worth $50,000 on 25 November 2019.
The largest trade he's ever made was buying 250,000 units of Onconova Therapeutics Inc stock on 25 November 2019 worth over $50,000. On average, Viren trades about 19,048 units every 165 days since 2013. As of 25 November 2019 he still owns at least 250,857 units of Onconova Therapeutics Inc stock.
You can see the complete history of Viren Mehta stock trades at the bottom of the page.
Dr. Viren Mehta, Ph.D., serves as Director of Onconova Therapeutics, Inc., since February 2004. Dr. Mehta has been a managing member of Mehta Partners since 1997. Mehta Partners provides strategic advisory services to the biotechnology and pharmaceutical companies worldwide. Prior to founding Mehta Partners, Dr. Mehta co-founded Mehta and Isaly in 1989, and prior to that was a part of the strategic planning team of the International Division at Merck & Co., or Merck. Dr. Mehta earned a Doctor of Pharmacy at the University of Southern California, and an M.B.A. from the Anderson School of Business at the University of California, Los Angeles.
Viren Mehta is 66, he's been the Director of Onconova Therapeutics Inc since 2004. There are 5 older and 7 younger executives at Onconova Therapeutics Inc. The oldest executive at Onconova Therapeutics Inc is Henry Bienen, 77, who is the Director.
Viren's mailing address filed with the SEC is C/O ONCONOVA THERAPEUTICS, INC, 12 PENNS TRAIL, NEWTOWN, PA, 18940.
Over the last 12 years, insiders at Onconova Therapeutics Inc have traded over $1,631,795 worth of Onconova Therapeutics Inc stock and bought 27,892,613 units worth $51,994,589 . The most active insiders traders include Capital, Llc Armistice Capi..., Capital Management, Llc 683 e Capital Partners L P Tyndall. On average, Onconova Therapeutics Inc executives and independent directors trade stock every 40 days with the average trade being worth of $294,478. The most recent stock trade was executed by Mark Patrick Guerin on 13 March 2024, trading 8,666 units of ONTX stock currently worth $8,666.
onconova therapeutics, inc. (nasdaq: ontx) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. using a proprietary chemistry platform, onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. onconova has three product candidates in clinical trials and six active pre-clinical programs. onconova seeks to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.
Onconova Therapeutics Inc executives and other stock owners filed with the SEC include: